COVID-19 |

The Interventions to Prevent and Treat Addictions (IPTA) study section reviews clinical applications aimed at developing, modifying, adapting, piloting or testing interventions to prevent the onset of addictive and related problem behaviors, prevent the progression of substance use to abuse, curtail the progression of substance abuse to dependence, prevent relapse, and treat substance use disorders and other addictive behaviors, at the individual level in humans.

Prevention and treatment interventions tested under both controlled (efficacy) and real-world (effectiveness) conditions are included.

The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.


  • Interventions to prevent substance use and progression toward addiction during critical developmental periods (e.g., adolescence, emerging adulthood) and across the lifespan.
  • Interventions to treat abuse of illicit drugs (including cocaine, heroin, marijuana, methamphetamine, new and emerging drugs) and alcohol, and related problems (e.g., substance-related violence and victimization); prescription drug misuse; nicotine dependence and use of alternative tobacco products. Interventions to treat other addictive behaviors (e.g., gambling disorder, internet addiction).
  • Pharmacotherapies and behavioral interventions.
  • Interventions among individuals with co-morbidity of addictions and other behavioral, medical, and psychological conditions.
  • Feasibility/pilot intervention trials, randomized controlled trials, and adaptive trial designs.
  • Trials examining the efficacy of interventions under controlled conditions and the effectiveness of efficacious interventions delivered in less controlled or uncontrolled situations or service settings.
  • Testing of new technologies or other methods for administering interventions.

Shared Interests and Overlaps

RPHB / Addiction Risks and Mechanisms (ARM): IPTA and ARM have a shared interest in substance use, addiction, and addictive behaviors. Applications focused on intervening at the individual level to prevent and treat addictive behaviors are reviewed in IPTA; applications focused on understanding the individual-level behaviors and mechanisms underlying substance use and abuse are reviewed in ARM, including biological, environmental, psychological, and neurocognitive factors that influence or predict the onset or trajectory of addictive behaviors.

RPHB / Psychosocial Development, Risk, and Prevention (PDRP): IPTA and PDRP have a shared interest in substance use interventions in adolescents. Applications focused broadly on addiction treatment are reviewed in IPTA; applications focused on interventions specifically related to social and developmental aspects are reviewed in PDRP.

HDM/ Community-Level Health Promotion (CLHP): IPTA and CLHP have a shared interest in interventions to prevent addictive health risks. Applications focused on addiction interventions at the individual level are reviewed in IPTA; applications focused on community-level interventions to prevent addictive behaviors in the general population are reviewed in CLHP.

RPHB / Biobehavioral Medicine and Health Outcomes (BMHO): IPTA and BMHO have a shared interest in pain management and opioid use. Applications focused on pain management in the context of opioid use disorder or the prevention of opioid misuse are reviewed in IPTA. Applications focused on the clinical use of prescribed opioids for pain management are reviewed in BMHO.

&HDM / Health Promotion in Communities (HPC): IPTA and HPC have a shared interest in preventing addiction. Applications focused on preventing addiction at the individual level are reviewed in IPTA. Applications focused on community-level interventions to prevent addiction in the general population are reviewed in HPC.